Novozymes A/s

Solvay Pharmaceuticals, Gmbh

Thomas Lenhard

Allan Svendsen

Signe Eskildsen Larsen

Lars Beier

Poul Erik Pedersen

Mads E Bjoernvad

Peter Colin Gregory

Tanja Maria Rosenkilde Kjaer

Mads Eskelund Bjoernvad

The invention provides methods of screening a microbial host cell for a property of interest in a microfluidic device, the method comprising the steps of: a) transforming a d-alanine racemase-deficient microbial host cell with a polynucleotide construct comprising: i) one or more polynucleotide region providing the property of interest when present in the host cell, and ii) at least one polynucleotide region complementing the d-alanine racemase deficiency when present in the host cell; and b) screening the transformed host cell for the property of interest in the microfluidic device in the absence of externally provided d-alanine.

Microfluidic device screening method

The invention relates to novel variants of a protease derived fromsp. (SEQ ID NO: 1) and closely related proteases, as well as their pharmaceutical use. The variants show improved performance in the treatment of pancreatic exocrine insufficiency (PEI). The variants may be combined with a lipase and/or an amylase. Other examples of medical indications are: Treatment of digestive disorders, pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.

Protease variants for pharmaceutical use

Growing community of inventors

Lyngby, Denmark

Thomas Lenhard